At the LSX (Life Sciences Executive) World Congress in Boston, leaders in biotech, healthtech, and medtech will gather to share trends, insights, and strategies for keeping on top of the va
Our round-up of financings in the biotech sector this week is led by BioAge Lab's filing of an initial public offering (IPO), with a placeholder target of $100 million, plus sizeable privat
Arsenal Biosciences has cleared an impressive $325 million from a third-round financing that will be used to fund clinical trials of its pipeline of CAR-T therapies, trying to break new gro
The BioIndustry Association (BIA) has asked new UK Chancellor Rachel Reeves for a nuanced approach to R&D tax credits in the upcoming budget, saying that the life sciences should not be
ReNeuron has become the latest UK biotech planning to cancel its listing on the AIM exchange, saying it has been unable to raise the capital it desperately needs to keep its business afloat
